Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01237301 · ClinicalTrials.gov registry record · NA
Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes
A NA study, sponsored by HealthPartners Institute.
- Completed
- Registry status
- NA
- Development phase
- 124
- Enrollment target
NCT01237301 is a NA study that has completed, run by HealthPartners Institute. The registered enrollment target is 124 participants.
The verdict
NCT01237301, a NA study, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the use of SMBG and CGM for clinical decisions related to the management of type 2 diabetes. The secondary objective is to determine the benefit of using CGM for clinical diabetes management decision-making.
Interventions
- DEVICE CGM Group
- DEVICE SMBG Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01237301
The ClinicalTrials.gov registry entry for NCT01237301 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CGM Group is the first listed.
NCT01237301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01237301 about?
NCT01237301 is a clinical study titled "Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes". The purpose of this study is to evaluate the use of SMBG and CGM for clinical decisions related to the management of type 2 diabetes. The secondary objective is to determine the benefit of using CGM for clinical diabetes management decision-making.
What is the current status of trial NCT01237301?
This trial is currently completed. It is a NA study. The enrollment target is 124 participants. The study started on 2010-10. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01237301?
The interventions under investigation include: CGM Group (DEVICE), SMBG Group (DEVICE).
Who is sponsoring clinical trial NCT01237301?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.